专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20060110394A1 Humanized anti-VLA 4 immunoglobulins and uses thereof 失效
标题翻译：人源化抗VLA 4免疫球蛋白及其用途
公开(公告)号：US20060110394A1
公开(公告)日：2006-05-25
申请号：US11006808
申请日：2004-12-08
申请人： Mary Bendig , Olivier Leger , Jose Saldanha , Tarran Jones , Ted Yednock
发明人： Mary Bendig , Olivier Leger , Jose Saldanha , Tarran Jones , Ted Yednock
IPC分类号： A61K39/395 , C07K16/30
CPC分类号： C07K16/2842 , A61K38/00 , A61K2039/505 , C07K16/2839 , C07K2317/24 , C07K2317/55 , C07K2317/565 , C07K2317/567 , C07K2317/92 , C07K2319/00 , G01N33/6872 , G01N2333/7055
摘要： The invention provides methods of treatment using humanized immunoglobulins that specifically bind to alpha-4 integrin. The methods are useful for treatment of asthma, atherosclerosis, AIDS dementia, diabetes, inflammatory bowel disease, rheumatoid arthritis, transplant rejection, graft versus host disease, tumor metastasis, nephritis, atopic dermatitis, psoriasis, myocardial ischemia, and acute leukocyte mediated lung injury.
摘要翻译：本发明提供使用特异性结合α-4整联蛋白的人源化免疫球蛋白的治疗方法。该方法可用于治疗哮喘，动脉粥样硬化，艾滋病痴呆，糖尿病，炎性肠病，类风湿性关节炎，移植排斥反应，移植物抗宿主病，肿瘤转移，肾炎，特应性皮炎，牛皮癣，心肌缺血和急性白细胞介导的肺损伤。

2. 发明授权

US08808999B2 Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof 有权
标题翻译：抗IGF-1R和/或抗胰岛素/ IGF-I杂合受体抗体及其用途
公开(公告)号：US08808999B2
公开(公告)日：2014-08-19
申请号：US13352599
申请日：2012-01-18
申请人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Alain Duflos , Jean-Francois Haeuw , Olivier Leger , Alain Beck
IPC分类号： C07K14/72 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732
摘要： The present invention relates to methods of identifying IGF-IR modulators and hybrid-R modulators comprising contacting IGF-IR with a humanized anti-IGF-IR antibody and contacting hybrid-R with a humanized anti-hybrid-R antibody, respectively.
摘要翻译：本发明涉及鉴定IGF-1R调节剂和杂合-R调节剂的方法，其包括将IGF-1R与人源化抗IGF-1R抗体接触并分别使杂交-R与人源化抗混合-R抗体接触。

3. 发明授权

US08715669B2 Anti-IL-17A/IL-17F cross-reactive antibodies 有权
标题翻译：抗IL-17A / IL-17F交叉反应抗体
公开(公告)号：US08715669B2
公开(公告)日：2014-05-06
申请号：US13339110
申请日：2011-12-28
申请人： Krzysztof Masternak , Olivier Leger
发明人： Krzysztof Masternak , Olivier Leger
IPC分类号： A61K39/395
CPC分类号： C07K16/244 , A61K2039/505 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： This invention provides fully human monoclonal antibodies that recognize IL-17F, the IL-17F homodimer, IL-17A, the IL-17A homodimer, and/or the heterodimeric IL-17A/IL-17F protein complex. The invention further provides methods of using such monoclonal antibodies as a therapeutic, diagnostic, and prophylactic.
摘要翻译：本发明提供了识别IL-17F，IL-17F同二聚体，IL-17A，IL-17A同二聚体和/或异二聚体IL-17A / IL-17F蛋白复合物的完全人单克隆抗体。本发明还提供使用这样的单克隆抗体作为治疗，诊断和预防的方法。

4. 发明授权

US07914784B2 Anti-IGF-IR antibodies and uses thereof 有权
标题翻译：抗IGF-1R抗体及其用途
公开(公告)号：US07914784B2
公开(公告)日：2011-03-29
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-François Haeuw , Alain Beck
IPC分类号： A61K39/395 , A61K39/00 , C12P21/08 , C07K16/18 , C07K16/28
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂的组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

5. 发明申请

US20100183619A1 Neutralizing Antibodies and Methods of Use Thereof 有权
标题翻译：中和抗体及其使用方法
公开(公告)号：US20100183619A1
公开(公告)日：2010-07-22
申请号：US12719561
申请日：2010-03-08
申请人： Greg Elson , Olivier Leger
发明人： Greg Elson , Olivier Leger
IPC分类号： A61K39/395 , C07K16/00 , A61P29/00 , A61P37/06 , A61P11/00
CPC分类号： C07K16/2896 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/24 , C07K2317/32 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76
摘要： This invention provides monoclonal antibodies that recognize the Toll-like Receptor 4/MD-2 receptor complex, and monoclonal antibodies that recognize the TLR4/MD2 complex as well as TLR4 when not complexed with MD-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics. This invention also provides soluble chimeric proteins, methods of expressing and purifying soluble chimeric proteins, and methods of using soluble chimeric proteins as therapeutics, in screening assays and in the production of antibodies.
摘要翻译：本发明提供识别Toll样受体4 / MD-2受体复合物的单克隆抗体，以及当与MD-2不复合时识别TLR4 / MD2复合物以及TLR4的单克隆抗体。本发明还提供使用人源化单克隆抗体作为治疗剂的方法。本发明还提供可溶性嵌合蛋白，表达和纯化可溶性嵌合蛋白的方法，以及在筛选测定和抗体生成中使用可溶性嵌合蛋白作为治疗剂的方法。

6. 发明申请

US20100183554A1 Anti-CD3 Antibodies and Methods of Use Thereof 有权
标题翻译：抗CD3抗体及其使用方法
公开(公告)号：US20100183554A1
公开(公告)日：2010-07-22
申请号：US12750385
申请日：2010-03-30
申请人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
发明人： Bernard Mach , Yann Dean , Marie Kosco-Vilbois , Greg Elson , Nicolas Fischer , Olivier Leger
IPC分类号： A61K39/395 , A61K38/21 , C07K16/28
CPC分类号： C07K16/2809 , A61K39/3955 , A61K45/06 , C07K2317/21 , C07K2317/34 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/74
摘要： The present invention is related to antibodies directed to the antigen CD3 and uses of such antibodies. In particular, the present invention provides fully human monoclonal antibodies directed to CD3. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
摘要翻译：本发明涉及针对抗原CD3的抗体和这种抗体的用途。特别地，本发明提供了完全针对CD3的人单克隆抗体。编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列，特别是对应于跨越框架区和/或互补决定区（CDR）的连续重链和轻链序列的序列，特别是从FR1至FR4或CDR1至CDR3 ，被提供。还提供了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。

7. 发明申请

US20100093087A1 IL-17 Mediated Transfection Methods 审中-公开
标题翻译： IL-17介导的转染方法
公开(公告)号：US20100093087A1
公开(公告)日：2010-04-15
申请号：US12575258
申请日：2009-10-07
申请人： Greg Elson , Mathias Contie , Nicolas Fouque , Olivier Leger , Yves Poitevin
发明人： Greg Elson , Mathias Contie , Nicolas Fouque , Olivier Leger , Yves Poitevin
IPC分类号： C12N5/00
CPC分类号： C07K14/54
摘要： The invention comprises compositions and methods for IL-17-mediated transfection that results in superior and enhanced properties of cell survival and protein production.
摘要翻译：本发明包括用于IL-17介导的转染的组合物和方法，其导致细胞存活和蛋白质生产的优异和增强的性质。

8. 发明申请

US20080286198A1 Novel anti-IGF-IR antibodies and uses thereof 有权
公开(公告)号：US20080286198A1
公开(公告)日：2008-11-20
申请号：US11783513
申请日：2007-04-10
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Alain Duflos , Jean-Francois Haeuw , Alain Beck
IPC分类号： A61K51/10 , C07H21/04 , C12N15/63 , C12N5/06 , A01K67/027 , C12P21/00 , G01N33/53 , C07K16/28 , A61K39/395 , A61P35/00 , A61K39/44
CPC分类号： A61K47/6805 , C07K2317/732 , Y10S425/81
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.

9. 发明申请

US20080193445A1 Novel anti-IGF-IR antibodies and uses thereof 审中-公开
标题翻译：新型抗IGF-1R抗体及其用途
公开(公告)号：US20080193445A1
公开(公告)日：2008-08-14
申请号：US11801080
申请日：2007-05-08
申请人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Nelly Kuklin , Michael Chastain
发明人： Liliane Goetsch , Nathalie Corvaia , Olivier Leger , Nelly Kuklin , Michael Chastain
IPC分类号： A61K39/395 , A61P35/00
CPC分类号： A61K39/3955 , A61K47/6803 , A61K47/6805 , A61K47/6807 , A61K47/6809 , A61K47/6819 , A61K47/6847 , A61K47/6913 , A61K2039/507 , C07K16/22 , C07K2317/732
摘要： The present invention relates to novel antibodies capable of binding specifically to the human insulin-like growth factor I receptor IGF-IR and/or capable of specifically inhibiting the tyrosine kinase activity of said IGF-IR receptor, especially monoclonal antibodies of murine, chimeric and humanized origin, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of these antibodies as a medicament for the prophylactic and/or therapeutic treatment of cancers overexpressing IGF-IR or any pathology connected with the overexpression of said receptor as well as in processes or kits for diagnosis of illnesses connected with the overexpression of the IGF-IR receptor. The invention finally comprises products and/or compositions comprising such antibodies in combination with anti-EGFR antibodies and/or compounds and/or anti-cancer agents or agents conjugated with toxins and their use for the prevention and/or the treatment of certain cancers.
摘要翻译：本发明涉及能够特异性结合人类胰岛素样生长因子I受体IGF-1R和/或能够特异性抑制所述IGF-1R受体的酪氨酸激酶活性的新型抗体，特别是鼠，嵌合体的单克隆抗体，人源化，以及编码这些抗体的氨基酸和核酸序列。本发明同样包括使用这些抗体作为用于预防和/或治疗过度表达IGF-1R的癌症或与所述受体的过度表达相关的任何病理学以及用于诊断与所述受体相关的疾病的过程或试剂盒 IGF-1R受体的过度表达。本发明最终包括包含抗体与抗EGFR抗体和/或化合物和/或与毒素缀合的抗癌剂或试剂组合的产品和/或组合物及其用于预防和/或治疗某些癌症的用途。

10. 发明申请

US20060263363A1 Anti-interferon gamma antibodies and methods of use thereof 有权
标题翻译：抗干扰素γ抗体及其使用方法
公开(公告)号：US20060263363A1
公开(公告)日：2006-11-23
申请号：US11342020
申请日：2006-01-27
申请人： Walter Ferlin , Nicolas Fischer , Greg Elson , Olivier Leger
发明人： Walter Ferlin , Nicolas Fischer , Greg Elson , Olivier Leger
IPC分类号： A61K39/395 , C07K16/24
CPC分类号： C07K16/249 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , C07K2317/21 , C07K2317/33 , C07K2317/565 , C07K2317/622 , C07K2317/76 , C07K2317/92
摘要： The invention relates to fully human antibodies, and fragments thereof, that bind to human interferon gamma (hIFNγ), thereby modulating the interaction between IFNγ and its receptor, IFNγ-R, and/or modulating the biological activities of IFN-γ. The invention also relates to the use of such anti-IFNγ antibodies in the prevention or treatment of immune-related disorders and in the amelioration of a symptom associated with an immune-related disorder.
摘要翻译：本发明涉及与人类干扰素γ（hIFNgamma）结合的完全人抗体及其片段，从而调节IFNγ与其受体之间的相互作用，IFNγ-R和/或调节IFN-γ的生物学活性。本发明还涉及这种抗-γ-抗原γ抗体在预防或治疗免疫相关病症中以及改善与免疫相关病症相关症状的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式